Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ComboPlus: Combination Pharmacological Interventions for OSA
NCT03892772Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of atomoxetine, oxybutynin and acetazolamide in obstructive sleep apnea (OSA) (4 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Apnea-hypopnea index at 3 days and Arousal Index at 3 days. Started Jan 2019; status: completed.
02
Drugs
atomoxetineoxybutyninacetazolamide
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT03892772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892772.